These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 38148378)

  • 21. Screening anthelmintic resistance to triclabendazole in Fasciola hepatica isolated from sheep by means of an egg hatch assay.
    Robles-Pérez D; Martínez-Pérez JM; Rojo-Vázquez FA; Martínez-Valladares M
    BMC Vet Res; 2015 Aug; 11():226. PubMed ID: 26314580
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vivo assessment of closantel ovicidal activity in Fasciola hepatica eggs.
    Solana MV; Mera y Sierra R; Scarcella S; Neira G; Solana HD
    Exp Parasitol; 2016 Jan; 160():49-53. PubMed ID: 26551411
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clonal amplification of Fasciola hepatica in Galba truncatula: within and between isolate variation of triclabendazole-susceptible and -resistant clones.
    Hodgkinson JE; Cwiklinski K; Beesley N; Hartley C; Allen K; Williams DJL
    Parasit Vectors; 2018 Jun; 11(1):363. PubMed ID: 29941045
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increase of carboxylesterase activity in Fasciola hepatica recovered from triclabendazole treated sheep.
    Scarcella S; Miranda-Miranda E; Cossío-Bayúgar R; Ceballos L; Fernandez V; Solana H
    Mol Biochem Parasitol; 2012 Oct; 185(2):151-3. PubMed ID: 22814337
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of the P-glycoprotein inhibitor, R(+)-verapamil on the drug susceptibility of a triclabendazole-resistant isolate of Fasciola hepatica.
    Savage J; Meaney M; Brennan GP; Hoey E; Trudgett A; Fairweather I
    Vet Parasitol; 2013 Jul; 195(1-2):72-86. PubMed ID: 23597772
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Unchanged triclabendazole kinetics after co-administration with ivermectin and methimazole: failure of its therapeutic activity against triclabendazole-resistant liver flukes.
    Ceballos L; Moreno L; Alvarez L; Shaw L; Fairweather I; Lanusse C
    BMC Vet Res; 2010 Feb; 6():8. PubMed ID: 20128898
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fasciola hepatica: histological demonstration of apoptosis in the reproductive organs of flukes of triclabendazole-sensitive and triclabendazole-resistant isolates, and in field-derived flukes from triclabendazole-treated hosts, using in situ hybridisation to visualise endonuclease-generated DNA strand breaks.
    Hanna RE; Forster FI; Brennan GP; Fairweather I
    Vet Parasitol; 2013 Jan; 191(3-4):240-51. PubMed ID: 23062689
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activity of cumin essential oil to control fascioliasis: Efficacy and changes in the tegument of Fasciola hepatica.
    Brauner de Mello A; Baccega B; Obelar Martins F; Ignês de Santi I; Islabão YW; de Giacometi M; Pereira Soares M; da Rosa Farias NA; Belmonte Oliveira C
    Exp Parasitol; 2023 Sep; 252():108587. PubMed ID: 37454922
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Resistance-induced changes in triclabendazole transport in Fasciola hepatica: ivermectin reversal effect.
    Mottier L; Alvarez L; Fairweather I; Lanusse C
    J Parasitol; 2006 Dec; 92(6):1355-60. PubMed ID: 17304820
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Isothermal microcalorimetry to study the activity of triclabendazole and its metabolites on juvenile and adult Fasciola hepatica.
    Keiser J; Manneck T; Kirchhofer C; Braissant O
    Exp Parasitol; 2013 Mar; 133(3):265-8. PubMed ID: 23206957
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-helminthic activity of Momordica charantia L. against Fasciola hepatica eggs after twelve days of incubation in vitro.
    Pereira CAJ; Oliveira LLS; Coaglio AL; Santos FSO; Cezar RSM; Mendes T; Oliveira FLP; Conzensa G; Lima WS
    Vet Parasitol; 2016 Sep; 228():160-166. PubMed ID: 27692319
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A major locus confers triclabendazole resistance in Fasciola hepatica and shows dominant inheritance.
    Beesley NJ; Cwiklinski K; Allen K; Hoyle RC; Spithill TW; La Course EJ; Williams DJL; Paterson S; Hodgkinson JE
    PLoS Pathog; 2023 Jan; 19(1):e1011081. PubMed ID: 36701396
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fasciola hepatica: ultrastructural effects of a combination of triclabendazole and clorsulon against mature fluke.
    Meaney M; Allister J; McKinstry B; McLaughlin K; Brennan GP; Forbes AB; Fairweather I
    Parasitol Res; 2007 Apr; 100(5):1091-104. PubMed ID: 17180691
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A single amino acid substitution in isozyme GST mu in Triclabendazole resistant Fasciola hepatica (Sligo strain) can substantially influence the manifestation of anthelmintic resistance.
    Fernández V; Estein S; Ortiz P; Luchessi P; Solana V; Solana H
    Exp Parasitol; 2015 Dec; 159():274-9. PubMed ID: 26542261
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of a field isolate of Fasciola hepatica resistant to albendazole and susceptible to triclabendazole.
    Sanabria R; Ceballos L; Moreno L; Romero J; Lanusse C; Alvarez L
    Vet Parasitol; 2013 Mar; 193(1-3):105-10. PubMed ID: 23273779
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of flukicides against Fasciola hepatica and first report of triclabendazole resistance on German sheep farms.
    Kahl A; von Samson-Himmelstjerna G; Helm C; Hodgkinson J; Williams D; Weiher W; Terhalle W; Steuber S; Ganter M; Krücken J
    Int J Parasitol Drugs Drug Resist; 2023 Dec; 23():94-105. PubMed ID: 38006779
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Time-course and accumulation of triclabendazole and its metabolites in bile, liver tissues and flukes collected from treated sheep.
    Moreno L; Ceballos L; Fairweather I; Lanusse C; Alvarez L
    Exp Parasitol; 2014 Jan; 136():14-9. PubMed ID: 24211244
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug resistance in liver flukes.
    Fairweather I; Brennan GP; Hanna REB; Robinson MW; Skuce PJ
    Int J Parasitol Drugs Drug Resist; 2020 Apr; 12():39-59. PubMed ID: 32179499
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ovicidal in vitro activity of 2-aryl-3-(2-morpholinoethyl)thiazolidin-4-ones and 2-aryl-3-(3-morpholinopropyl)thiazolidin-4-ones against Fasciola hepatica (Linnaeus, 1758).
    Zehetmeyr FK; da Silva MAMP; Pereira KM; Berne MEA; Cunico W; Campos JC; Gouvea DP; da Silva Nascente P; de Oliveira Hübner S; Siqueira GM
    Exp Parasitol; 2018 Sep; 192():60-64. PubMed ID: 30040962
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative assessment of the access of albendazole, fenbendazole and triclabendazole to Fasciola hepatica: effect of bile in the incubation medium.
    Alvarez LI; Mottier ML; Lanusse CE
    Parasitology; 2004 Jan; 128(Pt 1):73-81. PubMed ID: 15002906
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.